



Next-Generation Sequencing—Based Genomic Profiling of Children with Acute Myeloid Leukemia

Szylvia Krizsán,^{*†} Borbála Péterffy,^{*} Bálint Egyed,^{*†} Tibor Nagy,^{*‡} Endre Sebestyén,^{*} Lajos László Hegyi,^{*} Zsuzsanna Jakab,[†] Dániel J. Erdélyi,[†] Judit Müller,[†] György Péter,[§] Krisztina Csanádi,[§] Krisztián Kállay,[¶] Gergely Kriván,[¶] Gábor Barna,^{*} Gábor Bedics,^{*} Irén Haltrich,[†] Gábor Ottóffy,^{||} Katalin Csernus,^{||} Ágnes Vojcek,^{||} Lilla Györgyi Tiszlavicz,^{**} Krisztina Mita Gábor,^{**} Ágnes Kelemen,^{††} Péter Hauser,^{††} Zsuzsanna Gaál,^{‡‡} István Szegedi,^{‡‡} Anikó Ujfalusi,^{§§} Béla Kajtár,^{¶¶} Csongor Kiss,^{††} András Matolcsy,^{*|||} Botond Tímár,^{*} Gábor Kovács,[†] Donát Alpár,^{*} and Csaba Bödör^{*}

From the HCEMM-SE Molecular Oncohematology Research Group,^{*} Department of Pathology and Experimental Cancer Research, and Department of Pediatrics,[†] Semmelweis University, Budapest, Hungary; the Department of Biochemistry and Molecular Biology,[‡] Faculty of Medicine, the Department of Pediatric Hematology and Oncology,^{§§} Institute of Pediatrics, and the Department of Laboratory Medicine,^{§§} University of Debrecen, Debrecen, Hungary; the Hemato-Oncology Unit,[§] Heim Pal Children's Hospital, Budapest, Hungary; the Division of Pediatric Hematology and Stem Cell Transplantation,[¶] Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary; the Departments of Pediatrics^{||} and Pathology,^{¶¶} University of Pécs Clinical Centre, Pécs, Hungary; the Department of Pediatrics and Pediatric Health Care Center,^{**} University of Szeged, Szeged, Hungary; the Hemato-Oncology and Stem Cell Transplantation Unit,^{††} Velkey László Child's Health Center, Borsod-Abaúj-Zemplén County Central Hospital and University Teaching Hospital, Miskolc, Hungary; and the Division of Pathology,^{|||} Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

Accepted for publication
April 5, 2023.

Address correspondence to
Csaba Bödör, Ph.D., D.Sc.,
HCEMM-SE Molecular Onco-
hematology Research Group,
Department of Pathology and
Experimental Cancer Research,
Semmelweis University, 26
Üllői St., H-1085 Budapest,
Hungary.
E-mail: bodor.csaba1@
semmelweis.hu.

Pediatric acute myeloid leukemia (AML) represents a major cause of childhood leukemic mortality, with only a limited number of studies investigating the molecular landscape of the disease. Here, we present an integrative analysis of cytogenetic and molecular profiles of 75 patients with pediatric AML from a multicentric, real-world patient cohort treated according to AML Berlin-Frankfurt-Münster protocols. Targeted next-generation sequencing of 54 genes revealed 17 genes that were recurrently mutated in >5% of patients. Considerable differences were observed in the mutational profiles compared with previous studies, as *BCORL1*, *CUX1*, *KDM6A*, *PHF6*, and *STAG2* mutations were detected at a higher frequency than previously reported, whereas *KIT*, *NRAS*, and *KRAS* were less frequently mutated. Our study identified novel recurrent mutations at diagnosis in the *BCORL1* gene in 9% of the patients. Tumor suppressor gene (*PHF6*, *TP53*, and *WT1*) mutations were found to be associated with induction failure and shorter event-free survival, suggesting important roles of these alterations in resistance to therapy and disease progression. Comparison of the mutational landscape at diagnosis and relapse revealed an enrichment of mutations in tumor suppressor genes (16.2% versus 44.4%) and transcription factors (35.1% versus 55.6%) at relapse. Our findings shed further light on the heterogeneity of pediatric AML and identify previously unappreciated alterations that may lead to improved molecular characterization and risk stratification of pediatric AML. (*J Mol Diagn* 2023; 25: 555–568; <https://doi.org/10.1016/j.jmoldx.2023.04.004>)

Supported by the Hungarian National Research, Development and Innovation Office grants ED-18-1-2019-001 and FK20_134253 (C.B.) and K22_143021 (C.K.), the ERA PerMed GATA2-HuMo Funding Mechanism, the EU's Horizon 2020 research and innovation program (grant no. 739593) (C.B.), the János Bolyai Research Scholarship program (grant ID: BO/00125/22/5) of the Hungarian Academy of Sciences (D.A.), as well as by the Complementary Research Excellence Program of Semmelweis University (EFOP-3.6.3-VEKOP-16-2017-00009), the Ministry of

Innovation and Technology of Hungary from the New National Excellence Program (grant ÚNKP-22-5-SE-7) (D.A.), and the National Research, Development and Innovation Fund, financed under the TKP2021-EGA-24 and TKP2021-NVA-15 funding schemes and ELIXIR Hungary grants (C.B.).

D.A. and C.B. contributed equally as joint senior authors.
Disclosures: None declared.

Although pediatric acute myeloid leukemia (AML) constitutes only 20% of cases, it accounts for >40% of childhood leukemic mortality.¹ AML represents a heterogeneous malignant disease of myeloid progenitor cells characterized by the acquisition of recurrent genetic alterations. With the optimization of intensive chemotherapy regimens, treatment of pediatric AML has improved over the past decades, with current survival rates reaching 70% in developed countries. However, 30% of patients encounter relapse that still represents a major therapeutic challenge.^{2–8} With the advent of high-throughput technologies, identification of molecular alterations has revealed considerable molecular heterogeneity, both between and within individual patients, and expanded our knowledge of mechanisms underlying leukemogenesis, clonal expansion, and treatment resistance of leukemic cells.^{9–11} The widespread utilization of next-generation sequencing (NGS) led to the comprehensive characterization of patients with AML and to the discovery of novel, clinically relevant recurrent molecular aberrations, some of which represent important prognostic and predictive biomarkers.^{6,9,11}

Most reported studies investigating the molecular genetics of AML have focused on adult patients, with limited applicability to pediatric AML, as genetic profiles of adult and pediatric patients are substantially different.^{12,13} Several studies showed that pediatric and adult AML cases both have relatively low somatic mutation burden compared with other malignancies; however, genetic alterations most commonly occurring in adults are less frequently observed in pediatric patients with AML.^{13–17} Overall, the genetic landscape of pediatric AML is relatively undercharacterized due to the limited number of studies investigating the genetic background of childhood AML.^{13,14,18–24}

In the current study, we performed mutational profiling of 54 target genes in a real-world cohort of patients with pediatric AML using a panel-based targeted NGS approach combined with cytogenetic data obtained via standard karyotyping. The aim was to genetically characterize these patients and to investigate the clinical impact of the identified variants. Therapy-induced clonal evolution of leukemic cell populations was analyzed by using samples collected sequentially from the same patients at diagnosis and relapse. We describe the integrative cytogenetic and molecular profile of this pediatric AML cohort and show the widespread applicability of clinically relevant, NGS-based mutation profiling in the genetic characterization of pediatric AML.

Materials and Methods

Patients and Samples

Seventy-five patients with pediatric AML were included in this study, with a female:male ratio of 1:1.2. The median age at diagnosis was 9.0 years (range, 0 to 17 years), and the median white blood cell count was $8.9 \times 10^9/L$ (range, 0.51 to $348 \times 10^9/L$). Basic clinical and cytogenetic features of

the patient cohort are summarized in [Supplemental Table S1](#). Diagnostic bone marrow ($n = 70$) or peripheral blood ($n = 2$) samples from 72 children diagnosed with AML, as well as skin ($n = 1$) or lymph node ($n = 2$) samples from 3 children diagnosed with extramedullary AML, were analyzed. Diagnoses were established based on morphologic, immunophenotypic, and genotypic criteria at the Department of Pathology and Experimental Cancer Research, Semmelweis University, in the Department of Pathology, University of Pécs, or in the Department of Pathology, University of Debrecen, between 2003 and 2021 according to the classification system of the World Health Organization.²⁵ Patients were risk stratified and treated according to Berlin-Frankfurt-Münster (BFM) protocols, including AML-BFM 98, AML-BFM 2004, AML-BFM 2012, and AML-BFM 2019 ([Supplemental Table S2](#)). In addition to the diagnostic samples of 74 patients, nine samples drawn at the time of first relapse and three samples drawn at second relapse were investigated.

The median follow-up time was 23.8 months (range, 0.2 to 205.0 months). Additional clinical characteristics of patients are summarized in [Supplemental Table S2](#). DNA was extracted from the corresponding specimens (bone marrow, $n = 79$; peripheral blood, $n = 3$; skin, $n = 1$; lymph node, $n = 2$; and cerebrospinal fluid, $n = 1$) using the High Pure PCR Template Preparation Kit (Roche Life Science, Indianapolis, IN). Extracted DNA was quantified by using the Qubit dsDNA HS assay kit and Qubit 4.0 Fluorometer (Thermo Fisher Scientific, Waltham, MA).

Ethics Statement

Written informed consent was obtained from the patients' parents or guardians. The study was approved by the Medical Council Research of Hungary (IV/51-1/2022/EKU), and it was conducted in accordance with the Declaration of Helsinki.

Cytogenetic Analysis

Cytogenetic aberrations were determined by conventional G-banding and fluorescence *in situ* hybridization to detect abnormalities related to AML. Probes for *RUNX1::RUNX1T1*/t(8;21)(q22;q22) (ZytoVision, Bremerhaven, Germany), *CBFB::MYH11*/inv(16)(p13.1q22)/t(16;16)(p13.1;q22) (Abbott Molecular, Des Plaines, IL); *PML::RARA*/t(15;17)(q22;q12) (ZytoVision), and *KMT2A*/11q23 rearrangements (ZytoVision) were used for fluorescence *in situ* hybridization analysis. A complex karyotype was defined as three or more chromosomal aberrations in the absence of the recurrent AML genetic aberrations defined by using the World Health Organization classification, including t(8;21)(q22;q22), inv(16)(p13.1q22)/t(16;16)(p13.1;q22), t(15;17)(q22;q12), t(6;9)(p23;q34.1), *KMT2A*/11q23 rearrangement, or t(9;22)(q34;q11.2). Patients with core-binding factor (CBF)-AML characterized by inv(16)(p13.1q22), t(16;16)(p13;q22), t(8;21)(q22;q22), and t(15;17)

(q24;q21) were categorized in the favorable risk group; complex karyotype, monosomy 7, t(6;9)(p23;q34.1), inv(3)(q21;q26), t(4;11)(q21;q23), t(6;11)(q27;q23), and t(10;11)(p12;q23) were considered as adverse prognostic markers. Patients with normal karyotype and cytogenetic abnormalities not included in the aforementioned subgroups were classified into the intermediate-risk group.

Assessment of *FLT3*-Internal Tandem Duplication and *CEBPA* Mutational Status

Mutation analysis of *FLT3*-internal tandem duplication (ITD) was performed from genomic DNA using primers adapted from Kottaridis et al²⁶ (11F: 5'-FAM-GCAATTTAGGTAT-GAAAGCCAGC-3'; 12R: 5'-CTTTCAGCATTTTGACGG-CAACC-3'). Fluorescently labeled PCR products were analyzed by using a capillary electrophoresis 3500 Genetic Analyzer (Thermo Fisher Scientific) and GeneMapper software 5 (Thermo Fisher Scientific). The mutant *FLT3*-ITD allelic burden was calculated as the ratio of area under the mutant versus wild-type *FLT3* peak. For the assessment of the mutation status of *CEBPA*, the entire coding sequence was amplified by using three overlapping PCR fragments with previously described primer pairs [forward (F)1: 5'-TCGCCATGCCGGGAGAACTCTAAC-3', reverse (R)1: 5'-AGCTGCTTGGCTTCATCCTCCT-3', F2: 5'-GCTGGTGATCAAGCAGGAGC-3', R2: 5'-CCGCCACTCGCGCGGAGGTCG-3', F3: 5'-GGCAGCGCGCTCAAGGGGCTG-3', and R3: 5'-CACGGCTCGGGCAAGCCTCGAGAT-3'] and analyzed by using bidirectional Sanger sequencing.²⁷

Targeted NGS

Targeted NGS was performed by using the TruSight Myeloid Sequencing Panel (Illumina, San Diego, CA) covering 54 leukemia-associated genes (Supplemental Table S3). Individual libraries were prepared from 50 ng of genomic DNA according to the manufacturer's recommendations. DNA extracted from peripheral blood mononuclear cells of 15 healthy volunteers with normal complete blood profiles were used as negative control subjects. After quality control and equimolar pooling, libraries were sequenced on a NextSeq 550 platform (Illumina) using v2.5 chemistry with 150 bp paired-end configuration.

Bioinformatics Analysis

Raw sequencing data generated from TruSight Myeloid libraries were analyzed by using the TruSeq Amplicon app in BaseSpace Sequence Hub (Illumina). After demultiplexing and FASTQ file generation, reads were aligned against the GRCh37 reference human genome with a custom banded Smith-Waterman aligner. Single-nucleotide polymorphisms and short insertions or deletions were identified using the Genome Analysis Toolkit (Broad Institute, Cambridge, MA; <https://gatk.broadinstitute.org>). Variants were further

processed by using a custom Snakemake pipeline.²⁸ SnpSift version 4.3t (<https://pcingola.github.io/SnpEff>) was used for annotating variants with dbSNP version 20180423 (<https://www.ncbi.nlm.nih.gov/snp>), ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar>, last accessed July 6, 2020), or COSMIC version 92 (<https://cancer.sanger.ac.uk/cosmic>) coding mutations. In addition, ENSEMBL VEP (<https://www.ensembl.org/info/docs/tools/vep/index.html>, last accessed June 26, 2020; annotation data set downloaded at the same time) was used for annotating variant consequences or impact, and allele frequency data from the 1000 Genomes, gnomAD, or ESP projects.




For reliable detection of high-confidence mutations, variants were filtered based on several criteria: for each sample, variants were excluded if coverage was <100 reads, <20 reads supported the variant allele, or the variant allele frequency (VAF) was <5%. Synonymous variants and known single-nucleotide polymorphisms were excluded (based on an overall population allele frequency of >1% according to the gnomAD database).

Digital Droplet PCR

Screening and quantitative assessment of the *FLT3* p.D835Y mutation were performed by digital droplet PCR using a mutation-specific assay for *FLT3* p.D835Y (assay ID: dHsaMDV2010047; Bio-Rad Laboratories, Hercules, CA). Reactions were performed according to the manufacturer's recommendations. Droplets were generated by using the QX200 Automated Droplet Generator (Bio-Rad Laboratories) followed by fluorescent signal detection with the QX200 Droplet Reader system (Bio-Rad Laboratories). Results were evaluated and quantified by using QuantaSoft software version 1.7 (Bio-Rad Laboratories). Allelic burden of the mutation was defined as fractional abundance calculated from the ratio of the number of mutant DNA molecules (a) and the total number of mutant (a) plus wild-type (b) DNA molecules detected: fractional abundance = a/(a + b). Sensitivity of the digital droplet PCR analysis was assessed for each sample; the lower limit of the quantitative range could ubiquitously be determined as 0.01%.

Statistical Methods

Event-free survival (EFS) and overall survival (OS) were estimated by using the Kaplan–Meier method and compared statistically by using the log-rank test. Complete remission was defined as <5% blasts in the bone marrow, no evidence of leukemia at any other site, and evidence of regeneration of normal hematopoietic cells. OS was calculated from the date of diagnosis to exit or last follow-up. EFS was calculated from the date of diagnosis to the first event (induction failure, relapse, or death) or to the date of the last follow-up (death from early toxicity was excluded). Patients who failed to achieve complete remission at day 60 were considered as failures.



Comparisons between patient subgroups were performed by using the *U*-test for continuous variables and by the χ^2 or Fisher exact test for categorical variables. All statistical tests were performed by using GraphPad Prism software version 9.2.0 (GraphPad Software, La Jolla, CA).

Results

Cytogenetic Characteristics of Patients at Diagnosis

Cytogenetic results were available in 71 cases, with normal karyotype detected in 21.3% ($n = 16$) of the patients (Supplemental Table S1). *KMT2A* (*MLL*)-rearrangements were the most frequently [$n = 16$ (21.3%)] observed cytogenetic aberrations, followed by CBF-rearrangements [$n = 10$ (13.3%): t(8;21) translocations ($n = 7$) and inv(16)/t(16;16) alterations ($n = 3$). Eleven patients had karyotype associated with adverse prognosis [complex karyotype, monosomy 7, t(6;9) or inv(3)]. Overall, 20.0% of the patients ($n = 15$) were characterized by “other” aberrations (ie, cytogenetic abnormalities not classified in the aforementioned subgroups) (Figure 1A). The cytogenetic categories displayed an age-related distribution, with younger children harboring *KMT2A*-rearrangement and “other” aberrations more frequently, whereas the abundance of CBF-rearrangements and adverse karyotype increased with age (Figure 1B).

Genomic Profiling Using Targeted NGS

Targeted NGS with an average allelic depth of 4960 $\times$ revealed, in total, 154 single nucleotide variants and short insertions/deletions in the diagnostic samples of 74 patients (Figure 2A and Supplemental Table S4). The number of mutations identified in patients at diagnosis showed uneven distribution across specific cytogenetic subgroups, although these differences were not statistically significant (Figure 1C). The median number of mutations per patient was 2.0 (range, 0 to 18), with the highest rate of mutations in cytogenetically normal AML (CN-AML) (3.0) and the lowest in *KMT2A*-rearranged AML (1.0). In terms of mutation classes, missense and frameshift mutations were the most commonly detected, followed by duplications and splice site variants (Supplemental Figure S1 and Figure 2B). Distribution of VAFs exhibited heterogeneity, with most genes being affected by both subclonal and clonal alterations. Mutations in *ASXL1*, *CBL*, *ETV6*, *IDH1*, and *NPM1* emerged with a VAF of >30% in all cases (Supplemental Figure S2). Overall, 83.8% (62 of 74) of patients carried

at least one mutation in genes analyzed by NGS. Considering all genetic alterations detected by different modalities including cytogenetics, aberrations were identified in 98.6% (73 of 74) of patients (Figure 2A).

The most common class of mutations involved genes controlling kinase signaling [36.7% ($n = 65$)] and encoding transcription factors [20.9% ($n = 37$)], followed by chromatin modifiers [15.3% ($n = 27$)], tumor suppressors [9.6% ($n = 17$)], DNA methylation [5.6% ($n = 10$)], cohesion genes [5.6% ($n = 10$)], and RNA splicing [3.4% ($n = 6$)] (Figure 2A and Supplemental Figure S3). Figure 3A depicts the pairwise co-occurrence of the mutations in the different functional subgroups. Mutations associated with activated signaling commonly emerged together and with mutations of genes encoding transcription factors and epigenetic modifiers, whereas *NPM1* and epigenetic modifier mutations were mutually exclusive (Figure 3B). Mutations of kinase signaling genes were found in 60.8% of patients spread across all subtypes.

Of the 54 genes examined, 40 genes were altered in our cohort, with 17 genes recurrently mutated in >5% of patients. *FLT3* [24% (18 of 74)], *NRAS* [14% (10 of 74)], and *GATA2* [11% (8 of 74)] represented the most frequently mutated genes (Figure 2A). *FLT3*-ITDs were detected in 14.9% (11 of 70) of the diagnostic patient samples, including a total of 17 *FLT3*-ITD mutations with a median allelic ratio of 0.09 (range, 0.02 to 4.91), whereas length of ITD varied between 6 and 96 bp (Supplemental Table S5). The majority [63.6% (7 of 11)] of *FLT3*-ITD—positive cases carried a single mutation, whereas 18.2% (2 of 11) of patients harbored two mutations and 18.2% (2 of 11) harbored three mutations. As expected, *FLT3*-ITD mutations were predominantly present in patients with CN-AML [27% (4 of 15)] and CBF-AML [20% (2 of 10)].

Following *FLT3*-ITD mutations, alterations of the tyrosine kinase domain (TKD) of *FLT3* was the most frequently observed, as *FLT3*-TKD mutations were present in 8.1% (6 of 74) of patients: mutations occurred in codons 835 ($n = 4$), 836 ($n = 1$), and 841 ($n = 1$). Of the six patients with an *FLT3*-TKD mutation, four patients had *KMT2A*-rearrangement; conversely, 31.0% (5 of 16) of patients with *KMT2A*-rearrangements harbored *FLT3* mutation, and interestingly, no *FLT3*-ITD mutation was found in this subgroup (only *FLT3*-TKD). In addition, a single patient harbored a point mutation at the juxtamembrane domain of *FLT3*.

RAS pathway mutations (*NRAS*, *KRAS*, *PTPN11*, and *CBL*) were present in 27.0% (20 of 74) of patients and mainly occurred in *KMT2A*-rearranged cases and CN-AML. Most *NRAS* mutations (7 of 10) were found at codon 61, whereas mutations at codon 12 and 13 were detected in 2

Figure 1 **A:** Pie chart showing the frequency of the major cytogenetic subgroups in pediatric acute myeloid leukemia. Favorable risk cytogenetic groups are shown in green, the poor-risk groups in orange, and the intermediate-risk group subgroups in blue. **B:** Distribution of the cytogenetic subgroups according to age groups. Cytogenetics appeared different according to age groups, with younger children harboring *KMT2A*-rearrangement and “other” aberrations more frequently, whereas the ratio of core-binding factor rearrangement (CBF-r) increased with age. **C:** Number of mutations detected at diagnosis according to cytogenetic subgroup. Highest mutation rate was detected in normal karyotype acute myeloid leukemia and karyotypes associated with adverse prognosis.




Figure 2 **A:** Heat map displaying the somatic variants detected in the 54 target genes analyzed in the diagnostic samples of 74 pediatric patients with acute myeloid leukemia. Illustrated is the distribution of the somatic variants, age groups, and cytogenetic profiles as determined by karyotyping or fluorescence *in situ* hybridization, as well as the mutation frequency of the individual genes for all cases. **B:** Bar graph depicting the total number of mutations detected in individual genes ranked in order of recurrence. Mutation types are distinguished by different colors. NA, not available.

cases and 1 case, respectively. The median VAF of *NRAS* mutations was 35% (7% to 74%).

NPM1 mutations were detected in 6.8% (5 of 74) of patients. Four of the five mutations had been previously reported: three patients had type A mutation (c.863_864dupTCTG), one patient had type J mutation (c.863_864insCCGG), and one patient presented with a novel *NPM1* mutation (c.869_873delinsCCCTTTCCC). Four of the five patients with *NPM1* mutation harbored concomitant *FLT3* mutations. *NPM1* mutation was

associated with normal karyotype ($P = 0.0015$), in line with previous publications.^{13,29}

KDM6A mutations were present in 8.1% of patients (6 of 74) at diagnosis with close association with CBF-rearrangements, as 30% (3 of 10) of patients with CBF-AML harbored *KDM6A* mutations ($P = 0.0343$). Notably, *KDM6A* mutations were restricted to patients with t(8;21) AML, whereas they were absent in inv(16)/t(16;16). Regarding CBF-rearranged AML, no enrichment of *KIT* or *RAS* mutations was found in this subgroup of our cohort.




Figure 3 **A:** Circos plot diagram illustrating the pairwise co-occurrence of molecular aberrations based on the functional groups. **B:** Mutations associated with activated signaling commonly emerge together and with mutations of genes encoding transcription factors and epigenetic modifiers. Mutations of tumor suppressor genes occur concomitantly with mutations of other functional groups.

In addition to genes with known mutational hotspots (*NRAS*, *FLT3*, *IDH1*, *ASXL1*, and *SRSF2*), recurrent variants were detected in *CUX1* and *BCORL1* genes. *CUX1* c.1573C>G p.Leu525Val and c.1613A>G p.Asp538Gly variants were detected in 2 and 2 patients, respectively, with VAFs ranging from 6% to 44%. Overall, *CUX1* mutations were detected in 8% (6 of 74) of patients, predominantly associated with CN-AML (5 of 6; $P = 0.0013$). Nine percent (7 of 74) of patients carried *BCORL1* mutations, including a recurrent frameshift mutation (c.2541del p.Ser848ValfsTer5) identified in three patients, not previously described.

The entire coding region of the *CEBPA* gene was screened in 68 patients. *CEBPA* mutations were detected in three patients (4.4%), all of whom harbored both N- and C-terminal type of mutations. All *CEBPA* mutations are summarized in [Supplemental Table S6](#). Two novel frameshift mutations were identified (c.950_953delinsACCTT p.Leu317HisfsTer4; c.691_701del p.Val232AlafsTer85) in our cohort. Of the three children with *CEBPA* mutations, two had *de novo* AML with normal karyotype, and one patient presented with therapy-associated AML with complex karyotype.

Comparative Analysis of Mutational Profiles at Diagnosis and Relapse

To uncover progression-related changes in mutational profile, targeted NGS analysis was performed on matched diagnosis–relapse samples of eight patients with pediatric AML. Overall, nine first-relapse samples and three second-relapse samples were analyzed (in a single case, no diagnostic DNA sample was available). The relapse samples carried a slightly higher number of mutations compared with the diagnostic samples, with an average of 2.5 mutations (range, 1 to 6) per sample in the relapsed cohort (versus 2.0 at diagnosis). Overall, 61.5% (8 of 13) of initially detected mutations persisted at relapse, and 38.5% (5 of 13) of mutations were detected only in the diagnostic sample; 65.4% of

mutations (17 of 26 relapse mutation) emerged during disease progression. Mutations that persisted from diagnosis to relapse had a higher VAF at diagnosis compared with those that were eliminated at relapse (median VAF at diagnosis, 30.7% versus 10.9%). However, due to the relatively limited number of analyzed samples, this did not reach statistical significance. At relapse, mutations were identified in 16 genes, with *WT1* [42% (5 of 12)], *FLT3* [42% (5 of 12)], *NRAS* [33% (4 of 12)], and *NPM1* [25% (3 of 12)] representing the top four affected genes ([Figure 4](#)). Comparison of the function of the affected genes at diagnosis and relapse revealed enrichment of mutations of genes affecting tumor suppression (16.2% versus 44.4%) and transcription factors (35.1% versus 55.6%) at relapse ([Figure 4](#)).

Comparison of matching mutation profiles between clones dominating at diagnosis and relapse revealed three different patterns: (1) completely identical mutational profiles were observed in two patients (Patient 43 and Patient 62) at diagnosis and relapse ([Supplemental Figures S4 and S5](#)); (2) in five patients, the founding clone in the primary tumor gained additional mutations and evolved into the relapsed clone ([Supplemental Figures S6–S10](#)); and (3) in a single patient, the mutation profile slightly changed from diagnosis to relapse, as the initially detected *FLT3*-TKD mutated sub-clone was eradicated by the chemotherapy ([Supplemental Figure S11](#)). Patient 75 ([Supplemental Figure S12](#)) relapsed >3 years after the initial diagnosis and presented with an entirely different leukemic clone, not only in terms of the mutation profile but also the immunophenotype and the karyotype. At diagnosis, this patient presented with CN-AML with *NPM1* mutation (no DNA sample was available for targeted NGS), while at first relapse the *NPM1* mutation was eradicated and, in the meantime, monosomy 7, *NRAS*, and *WT1* mutations emerged, raising the possibility that instead of a clonally related relapse, the patient had developed therapy-related AML. After allogeneic hematopoietic stem cell transplantation, the patient experienced a second




Figure 4 Heat map displaying the mutational status of nine patients at the time of diagnosis and relapse. Stable mutations (ie, present at diagnosis and relapse) and unstable mutations (ie, present either only at diagnosis or at relapse) are shown with different colors [DNA was not available from Patient 75 to perform next-generation sequencing (NGS) analysis at diagnosis, although the *NPM1* mutational status was known]. NA, not available; Pt, patient.

relapse from the clone detected at the first relapse carrying monosomy 7 with a newly acquired subclonal *CUX1* mutation (the presence of *NRAS*, *WT1*, and *CUX1* variants in the diagnostic sample could not be tested due to lack of DNA sample for targeted NGS).

With the exception of two patients (Patient 40 and Patient 3) who relapsed very early and showed active clonal evolution, time from diagnosis until the first relapse suggested a prolonged time requirement of clonal evolution from a founding clone compared with the quick return of an identical clone at the time of relapse (median, 24.5 versus 9.5 months) (Supplemental Figures S9 and S10).

To gain further insights into the clonal dynamics, Patient 36, who had samples available from multiple disease time points, was studied. The patient initially presented with *NPM1*, *FLT3*-ITD, and *GATA2* mutations at diagnosis; 2 years later, she eventually relapsed with a clone carrying the original *NPM1* mutation and a newly acquired *BCOR* mutation. Shortly after achieving complete remission, a second relapse evolved with the same *NPM1* mutation accompanied by a novel *FLT3* D835Y mutation. Interestingly, the *FLT3* D835Y mutation was detectable by digital droplet PCR with a low VAF (1.67%) as early as the time of the first relapse, and the mutation was still present when the patient achieved second complete remission with measurable residual disease positivity after two courses of salvage chemotherapy (VAF, 0.19%) (Supplemental Figure S3D).

Clinical Outcome Based on Molecular Abnormalities

At 5 years, the EFS and OS for the whole cohort proved to be 50.0% and 56.2% (Supplemental Figures S13 and S14), respectively, with a median follow-up time of 23.8 months (range, 0.2 to 205 months). Risk classification based on cytogenetics and mutational status of *NPM1*, *CEBPA*, *FLT3*-ITD, and *WT1* showed that patients in the favorable-, intermediate-, and adverse-risk categories had significantly different 5-year EFS and OS [EFS, 90% versus 30% versus 18% ($P < 0.0001$); OS, 90% versus 42% versus 22% ($P = 0.0014$)] (Figure 5). Multiparametric flow cytometry data were available from 57 patients (Supplemental Table S7). Overall, 91.8% (56 of 61) of patients achieved complete remission after two courses of intensive chemotherapy, whereas three patients experienced fatal complications during the induction therapy, and two patients were non-responders. Due to the small number of patients, assessment of the prognostic significance of individual mutations was limited; only mutations in tumor suppressor genes (*TP53*, *PHF6*, and *WT1*) were significantly associated with induction failures (Fisher exact test, $P = 0.0034$) (Supplemental Table S8).

The prognostic significance of early response to treatment was studied at day 28. AML BFM protocols define >20% blasts on day 28 as poor response to treatment. Using this cutoff value, both the 5-year EFS and OS were significantly different between good and poor responders




Figure 5 Five-year overall survival (A) and event-free survival (B) rates according to favorable (yellow), intermediate (blue), and adverse (red) risk groups based on cytogenetic alterations and mutational status of *NPM1*, *CEBPA*, *FLT3*-internal tandem duplication, and *WT1*. Log-rank *P* value is indicated.

(57.3% versus 0%, $P < 0.0001$; 64.2% versus 28.6%, $P = 0.0414$).

Stratification based on AML-BFM protocols was as follows: patients with *RUNX1::RUNX1T1*, *CBFB::MYH11*, *PML::RARA*, normal karyotype with *NPM1*, or biallelic *CEBPA* mutations were categorized in the favorable subgroup. Patients with complex karyotype (ie, >3 aberrations), monosomy 7, t(6;9), inv(3), t(6;11), t(10;11) or

FLT3-ITD with *WT1* mutation belonged to the adverse risk group, with all remaining patients categorized as intermediate risk. The 5-year OS was 90.0% for patients with favorable prognosis, 42.3% for patients classified in the intermediate-risk group, and 22.2% among patients with unfavorable prognosis ($P = 0.0014$); the EFS values in these risk groups proved to be 90.0%, 30.0%, and 18.5%, respectively ($P < 0.0001$).

Discussion

Although the treatment efficacy of pediatric AML has improved over the past decades, primarily owing to increasingly intensified regimens, refined allograft indications, and supportive care, the clinical outcomes have plateaued, with 70% of patients achieving 5-year survival.^{2,30,31} Although the genomic background of AML has been widely studied, pediatric AML is less characterized, as only a limited number of studies have focused on investigating the molecular landscape of children with AML at diagnosis.^{13–16,19–21} Genomic profiling of pediatric AML revealed low tumor mutational burden similar to adult patients, with some shared recurrently mutated genes. However, the spectrum of genetic alterations in pediatric and adult patients with AML is remarkably different, suggesting that pathogenesis of pediatric AML differs from that of the adult AML.^{13,32} Consequently, not all findings related to adult patients with AML are applicable to children, justifying the need to further investigate the mutation profiles of pediatric patients with AML.

Pediatric patients with AML are known to harbor clonal chromosomal abnormalities more frequently compared with adult AML cases, and many of these cytogenetic alterations have prognostic significance.^{12,33–35} In the current study, distribution of patients in the various cytogenetic groups was consistent with previous reports, as abnormal karyotype was detected in 77.5% (55 of 71) of pediatric patients with AML, and *KMT2A*-rearrangement and normal karyotype were the two most commonly observed genotypes. The prognostic significance of individual chromosomal abnormalities could not be evaluated due to the limited number of patients; however, risk classification based on cytogenetics clearly discriminated favorable-, intermediate-, and adverse-risk groups in our patient cohort.

The panel-based targeted NGS approach enabled us to identify single nucleotide variants and insertions/deletions in 83.8% of patients, and by combining the results with cytogenetics, at least one molecular aberration was detected in 98.6% of patients. Despite investigating only a limited number of genes, each patient had a unique genomic profile due to the unique co-occurrence of mutations. As expected, the number of variants per case was relatively low, reflecting the low tumor mutational burden previously observed in pediatric AML.^{13,14}

KMT2A-rearranged cases tended to have fewer mutations than other subtypes of AML, in line with previous publications.^{19,20} *KMT2A*-rearrangements are associated with early-onset AML; however, in our cohort, more than one-half of patients with *KMT2A*-rearrangement were older than 2 years. An increased number of mutations were detected in patients with normal karyotype and karyotypes associated with adverse prognosis. In our cohort, the most common class of mutations involved genes that control kinase signaling and encode transcription factors, whereas

mutations in epigenetic components or spliceosome complexes commonly occurring in adult patients with AML were present less common, in line with the literature.^{9,17,36} Comparison of the mutation landscape revealed considerable differences in the mutational frequencies in some of the affected genes (Supplemental Figure S15).

RAS pathway mutations (*NRAS*, *KRAS*, *PTPN11*, and *CBL*) occurred less commonly in our cohort, as 27% of patients carried a RAS pathway mutation at diagnosis compared with 40% to 50% frequencies reported in previous publications.^{13,18,20,32} *KIT* mutations were less frequently observed, with only a single CBF-AML patient carrying a *KIT* mutation, while *KIT* mutations are detected at a significantly higher ratio (20% to 40%) in pediatric patients with CBF-AML in the literature. However, this may also be attributable to the low case number in this subgroup.^{37–39}

In our cohort, *BCORL1*, *CUX1*, *KDM6A*, *PHF6*, and *STAG2* mutations were detected at higher frequency than in any other previous publications predominantly using whole-genome sequencing and whole-exome sequencing.^{13,20,32,40} Mutations in *BCOR* and its homolog, *BCORL1*, were first described in adult AML presenting in 5% to 10% of patients (mostly detected in secondary- and therapy-related AML) associated with inferior outcome.^{41–43} In children with AML, *BCOR/BCORL1* mutations were present in only 2.9% to 3.4% of patients.^{13,19,20,40} Assessment of clonality using VAF values suggested that the vast majority of *BCOR/BCORL1* mutations were subclonal, which might explain the significantly higher frequency of *BCOR/BCORL1* mutations in our cohort.

Interestingly, *CUX1* mutations detected in 8% of our cohort were not identified in the previous pediatric AML studies based on whole-genome/whole-exome sequencing and were detected in only a single patient with pediatric AML by Tarlock et al using deep-sequencing.^{13,16,19,32} *CUX1* is a transcription factor regulating cell cycle progression and apoptosis and acts as a haploinsufficient tumor suppressor frequently impaired in myeloid neoplasms, mainly through loss of chromosome 7.^{9,44,45} *CUX1* mutations are associated with inferior prognosis in myeloid malignancies, similar to the adverse outcome of $-7/(del7q)$ myeloid malignancies.^{44,46} The higher frequency of *CUX1* mutations detected in our cohort may be explained by the use of deep sequencing that enabled us to identify *CUX1* mutations even at a subclonal level. *KDM6A* was recurrently altered in our cohort (8.1%) and associated with *RUNX1::RUNX1T1*-rearrangement, in contrast with previous publications in which *KDM6A* mutations were only described in 0.5% to 3% of pediatric patients with AML, and enrichment of *KDM6A* mutation has not been previously described in children with CBF-AML.^{16,21,32} However, studies on adult CBF-AML showed that mutations of chromatin modifiers (including *KDM6A* as well) were observed almost exclusively in AML with *RUNX1::RUNX1T1* fusion.^{47,48}

Another X-linked tumor suppressor gene recurrently mutated in our cohort was *PHF6*. *PHF6* mutations are rare events in pediatric AML, as only 1.4% to 3.6% of patients harbor *PHF6* mutations with an associated poor outcome.^{13,20,49} Recently, Stratmann et al⁵⁰ showed that mutational frequency of *PHF6* was substantially higher in relapsed or primary resistant patients than previously reported in diagnosis-only cohorts. This finding supports the association of *PHF6* mutations with poor outcome also reported in our study and by Marceau-Renaut et al.²⁰

Risk stratification of pediatric AML is mostly based on cytogenetics; however, some recurrent mutations such as *NPM1*, *CEBPA*, and *FLT3-ITD* with *WT1* are also included in most risk classifications.^{41,51} Recently, several publications suggested optimization of risk stratifications of AML by incorporating additional genetic lesions.^{52–55} The newly published risk classification of the European LeukemiaNet recommends mutational analysis of genes, including *BCOR*, *EZH2*, *SF3B1*, *SRSF2*, *STAG2*, *U2AF1*, and *ZRSR2* as these alterations are associated with high-risk features and adverse prognosis.⁵⁶ Unfortunately, prognostic stratifications developed for adults are not necessarily suitable for children; these initiatives draw attention, however, to the clinical need to further investigate how newly identified molecular alterations of pediatric AML could be incorporated into the current risk classifications.

Most studies in the field of pediatric AML have focused on the prognostic significance of a single gene or a subset of genes; however, the true heterogeneity of pediatric AML could not be captured with these approaches. Only a limited number of studies evaluated the prognostic significance of mutations in childhood AML in the era of high-throughput sequencing. The favorable prognostic impact of *NPM1* and *CEBPA* mutations has been well established for many years, whereas the prognostic significance of other molecular alterations is less defined.^{29,57–59} Marceau-Renaut et al²⁰ showed that *PHF6* and *RUNX1* mutations are associated with poor prognosis in childhood AML, and Umeda et al⁶⁰ showed that *UBTF* tandem duplication is a recurrent lesion in pediatric AML and is associated with poor outcomes. Due to the limited size of our cohort, the prognostic significance of individual mutations could not be comprehensively investigated. However, results from our current analysis suggest that tumor suppressor gene mutations (*PHF6*, *TP53*, and *WT1*) are associated with induction failure and a trend toward shorter EFS, although these findings will need to be confirmed in independent, larger studies.

Our study also compared the mutational landscape of eight matched diagnosis and relapse pediatric AML samples using panel-based targeted NGS. A slightly higher number of mutations was found at relapse compared with the diagnostic samples, and mutations persisting at relapse had higher VAF at diagnosis compared with those that were eliminated. Relapse-specific mutation could not be identified, although mutations in tumor suppressor genes and epigenetic modifiers occurred more frequently at relapse. In

five patients, relapsed AML evolved from one of the subclones detected at the initial diagnosis and was accompanied by several additional mutations that were absent or present at a lower allele frequency in the diagnostic sample, indicating the multistep process of leukemia recurrence. In contrast, two patients relapsed early with seemingly identical clones, suggesting the incomplete eradication of leukemic cells by the initial treatment.

Targeted NGS is a robust tool for the reliable detection of disease-relevant alterations that determine distinct genetic subgroups of pediatric AML and/or are associated with disease prognosis. The comprehensive profiling of recurrent genomic aberrations achieved by examining a high number of different genes also provides valuable information at both the time of diagnosis and relapse. Our results further show the versatile applicability of targeted NGS and strongly support its future incorporation into the clinical research and diagnostic workflow of pediatric patients with AML.

In summary, we performed an integrative analysis of cytogenetic and molecular profiles of pediatric AML from a multicentric, real-world patient cohort and identified previously unappreciated alterations, potentially leading to improved molecular characterization and risk stratification of patients with pediatric AML. To the best of our knowledge, this study is the first to characterize the mutational landscape of pediatric patients with AML treated according to AML BFM protocols in Central Europe. Our results also show that childhood AML represents a distinct entity that differs from adult AML in terms of the spectrum of gene mutations.

Acknowledgments

We thank the patients and their families involved in this study, and Fatima Abdul Kader, Adrienne Pallag, Stefánia Gróf, and Erik Zajta for excellent technical assistance.

Author Contributions

S.K. conceived the study, prepared the NGS library, collected and analyzed the data, performed statistical analysis, prepared the figures, and wrote the manuscript; B.P., B.E., D.J.E., J.M., G.P., G.Ba., I.H., G.O., K.Csa., K.K., G.Kr., K.Cse., Á.V., L.G.T., K.M.G., Á.K., P.H., Z.G., I.S., A.U., B.K., C.K., and G.Ko. provided patient samples and clinical data; Z.J. collected clinical data; L.L.H. prepared and sequenced the NGS library; E.S., G.Be. and T.N. performed bioinformatics analysis; A.M. and B.T. performed pathologic review and data analysis; C.B. and D.A. conceived the study, supervised the research, and reviewed the manuscript. All authors have read and given final approval of the manuscript to be published.

Supplemental Data

Supplemental material for this article can be found at <http://doi.org/10.1016/j.jmoldx.2023.04.004>.

References

1. Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, Kramer J, Siegel RL: Cancer treatment and survivorship statistics, 2022. *CA Cancer J Clin* 2022, 72:409–436
2. Zwaan CM, Kolb EA, Reinhardt D, Abrahamsson J, Adachi S, Aplenc R, De Bont ESJM, De Moerloose B, Dworzak M, Gibson BES, Hasle H, Leverger G, Locatelli F, Ragu C, Ribeiro RC, Rizzari C, Rubnitz JE, Smith OP, Sung L, Tomizawa D, van den Heuvel-Eibrink MM, Creutzig U, Kaspers GJL: Collaborative efforts driving progress in pediatric acute myeloid leukemia. *J Clin Oncol* 2015, 33:2949–2962
3. Rasche M, Zimmermann M, Borschel L, Bourquin J-P, Dworzak M, Klingebiel T, Lehmbecher T, Creutzig U, Klusmann J-H, Reinhardt D: Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. *Leukemia* 2018, 32:2167–2177
4. Sung L, Aplenc R, Alonzo TA, Gerbing RB, Lehmbecher T, Gams AS: Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group. *Blood* 2013, 121:3573–3577
5. Aplenc R, Meshinchi S, Sung L, Alonzo T, Choi J, Fisher B, Gerbing R, Hirsch B, Horton T, Kahwash S, Levine J, Loken M, Brodersen L, Pollard J, Raimondi S, Kolb EA, Gams A: Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. *Haematologica* 2020, 105:1879–1886
6. Gibson BES, Webb DKH, Howman AJ, De Graaf SSN, Harrison CJ, Wheatley K; United Kingdom Childhood Leukaemia Working Group; Dutch Childhood Oncology Group: Results of a randomized trial in children with acute myeloid leukaemia: Medical Research Council AML12 trial. *Br J Haematol* 2011, 155:366–376
7. Gaál Z, Jakab Z, Kárai B, Ujfalusi A, Petrás M, Kállay K, Kelemen Á, Simon R, Kriván G, Kovács GT, Kiss C, Szegedi I: Recent advances in the management of pediatric acute myeloid leukemia—report of the Hungarian Pediatric Oncology-Hematology Group. *Cancers (Basel)* 2021, 13:5078
8. Zarnegar-Lumley S, Caldwell KJ, Rubnitz JE: Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies. *Leukemia* 2022, 36:1951–1960
9. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O'Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, Döhner K, Schlenk RF, Döhner H, Campbell PJ: Genomic classification and prognosis in acute myeloid leukemia. *N Engl J Med* 2016, 374:2209–2221
10. Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci ND, Heguy A, Cherry A, Vance G, Higgins RR, Ketterling RP, Gallagher RE, Litzow M, van den Brink MRM, Lazarus HM, Rowe JM, Luger S, Ferrando A, Paietta E, Tallman MS, Melnick A, Abdel-Wahab O, Levine RL: Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. *N Engl J Med* 2012, 366:1079–1089
11. Miles LA, Bowman RL, Merlinsky TR, Csate IS, Ooi AT, Durruthy-Durruthy R, Bowman M, Famulare C, Patel MA, Mendez P, Ainali C, Demaree B, Delley CL, Abate AR, Manivannan M, Sahu S, Goldberg AD, Bolton KL, Zehir A, Rampal R, Carroll MP, Meyer SE, Viny AD, Levine RL: Single-cell mutation analysis of clonal evolution in myeloid malignancies. *Nature* 2020, 587:477–482
12. Creutzig U, Zimmermann M, Reinhardt D, Rasche M, von Neuhoff C, Alpermann T, Dworzak M, Perglerová K, Zemanova Z, Tchinda J, Bradtke J, Thiede C, Haferlach C: Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. *Cancer* 2016, 122:3821–3830
13. Bolouri H, Farrar JE, Triche T Jr, Ries RE, Lim EL, Alonzo TA, Ma Y, Moore R, Mungall AJ, Marra MA, Zhang J, Ma X, Liu Y, Liu Y, Auvil JMG, Davidsen TM, Gesuwan P, Hermida LC, Sallia B, Capone S, Ramsingh G, Zwaan CM, Noort S, Piccolo SR, Kolb EA, Gams AS, Smith MA, Gerhard DS, Meshinchi S: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. *Nat Med* 2018, 24:103–112
14. Radtke I, Mullighan CG, Ishii M, Su X, Cheng J, Ma J, Ganti R, Cai Z, Goorha S, Pounds SB, Cao X, Obert C, Armstrong J, Zhang J, Song G, Ribeiro RC, Rubnitz JE, Raimondi SC, Shurtleff SA, Downing JR: Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. *Proc Natl Acad Sci U S A* 2009, 106:12944–12949
15. Farrar JE, Schuback HL, Ries RE, Wai D, Hampton OA, Trevino LR, Alonzo TA, Guidry Auvil JM, Davidsen TM, Gesuwan P, Hermida L, Muzny DM, Dewal N, Rustagi N, Lewis LR, Gams AS, Wheeler DA, Smith MA, Gerhard DS, Meshinchi S: Genomic profiling of pediatric acute myeloid leukemia reveals a changing mutational landscape from disease diagnosis to relapse. *Cancer Res* 2016, 76:2197–2205
16. Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, Zhou X, Li Y, Rusch MC, Easton J, Huether R, Gonzalez-Pena V, Wilkinson MR, Hermida LC, Davis S, Sioson E, Pounds S, Cao X, Ries RE, Wang Z, Chen X, Dong L, Diskin SJ, Smith MA, Guidry Auvil JM, Meltzer PS, Lau CC, Perlman EJ, Maris JM, Meshinchi S, Hunger SP, Gerhard DS, Zhang J: Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. *Nature* 2018, 555:371–376
17. Cancer Genome Atlas Research Network, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al: Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med* 2013, 368:2059–2074
18. Olsson L, Zettermark S, Biloglav A, Castor A, Behrendtz M, Forestier E, Paulsson K, Johansson B: The genetic landscape of paediatric de novo acute myeloid leukaemia as defined by single nucleotide polymorphism array and exon sequencing of 100 candidate genes. *Br J Haematol* 2016, 174:292–301
19. Shiba N, Yoshida K, Shiraishi Y, Okuno Y, Yamato G, Hara Y, Nagata Y, Chiba K, Tanaka H, Terui K, Kato M, Park M-J, Ohki K, Shimada A, Takita J, Tomizawa D, Kudo K, Arakawa H, Adachi S, Taga T, Tawa A, Ito E, Horibe K, Sanada M, Miyano S, Ogawa S, Hayashi Y: Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia. *Br J Haematol* 2016, 175:476–489
20. Marceau-Renaut A, Duployez N, Ducourneau B, Labopin M, Petit A, Rousseau A, Geffroy S, Bucci M, Cuccini W, Fenneteau O, Ruminy P, Nelken B, Ducassou S, Gaudemer V, Leblanc T, Michel G, Bertrand Y, Baruchel A, Leverger G, Preudhomme C, Lapillonne H: Molecular profiling defines distinct prognostic subgroups in childhood AML: a report from the French ELAM02 study group. *Hemasphere* 2018, 2:e31
21. Liu T, Rao J, Hu W, Cui B, Cai J, Liu Y, Sun H, Chen X, Tang Y, Chen J, Wang X, Wang H, Qian W, Mao B, Guo S, Wang R, Liu Y, Shen S: Distinct genomic landscape of Chinese pediatric acute myeloid leukemia impacts clinical risk classification. *Nat Commun* 2022, 13:1640
22. Shiba N, Yoshida K, Hara Y, Yamato G, Shiraishi Y, Matsuo H, Okuno Y, Chiba K, Tanaka H, Kaburagi T, Takeuchi M, Ohki K, Sanada M, Okubo J, Tomizawa D, Taki T, Shimada A, Sotomatsu M, Horibe K, Taga T, Adachi S, Tawa A, Miyano S, Ogawa S, Hayashi Y: Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia. *Blood Adv* 2019, 3:3157–3169
23. Yang W, Qin M, Jia C, Yang J, Chen W, Luo Y, Jing Y, Wang B: Pediatric acute myeloid leukemia patients with KMT2A

- rearrangements: a single-center retrospective study. *Hematology* 2022, 27:583–589
24. Meena JP, Pathak N, Gupta AK, Bakhshi S, Gupta R, Makkar H, Seth R: Molecular evaluation of gene mutation profiles and copy number variations in pediatric acute myeloid leukemia. *Leuk Res* 2022, 122:106954
 25. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* 2016, 127:2391–2405
 26. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, Goldstone AH, Linch DC: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. *Blood* 2001, 98:1752–1759
 27. Burnett AK, Hills RK, Green C, Jenkinson S, Koo K, Patel Y, Guy C, Gilkes A, Milligan DW, Goldstone AH, Prentice AG, Wheatley K, Linch DC, Gale RE: The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. *Blood* 2010, 115: 948–956
 28. Köster J, Rahmann S: Snakemake—a scalable bioinformatics workflow engine. *Bioinformatics* 2012, 28:2520–2522
 29. Hollink IHIM, Zwaan CM, Zimmermann M, Arentsen-Peters TCJM, Pieters R, Cloos J, Kaspers GJL, de Graaf SSN, Harbott J, Creutzig U, Reinhardt D, van den Heuvel-Eibrink MM, Thiede C: Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. *Leukemia* 2009, 23:262–270
 30. Pui C-H, Carroll WL, Meshinchi S, Arceci RJ: Biology, risk stratification, and therapy of pediatric acute leukemias: an update. *J Clin Oncol* 2011, 29:551–565
 31. Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, Dimitrova N, Jakab Z, Kaatsch P, Lacour B, Mallone S, Marcos-Gragera R, Minicozzi P, Sanchez-Perez M-J, Sant M, Santaquilani M, Stiller C, Tavilla A, Trama A, Visser O, Peris-Bonet R, EUROCORE Working Group: Childhood cancer survival in Europe 1999-2007: results of EUROCORE-5—a population-based study. *Lancet Oncol* 2014, 15:35–47
 32. Tarlock K, Zhong S, He Y, Ries R, Severson E, Bailey M, Morley S, Balasubramanian S, Erlich R, Lipson D, Otto GA, Vergillo J-A, Kolb EA, Ross JS, Mughal T, Stephens PJ, Miller V, Meshinchi S, He J: Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling. *Oncotarget* 2018, 9:26417–26430
 33. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK; National Cancer Research Institute Adult Leukaemia Working Group: Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. *Blood* 2010, 116: 354–365
 34. Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DK, Wheatley K, de Graaf SSN, van den Berg E, Burnett AK, Gibson BES: Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. *J Clin Oncol* 2010, 28:2674–2681
 35. Quessada J, Cuccuini W, Sautier P, Loosveld M, Harrison CJ, Lafage-Pochitaloff M: Cytogenetics of pediatric acute myeloid leukemia: a review of the current knowledge. *Genes (Basel)* 2021, 12:924
 36. Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al: Functional genomic landscape of acute myeloid leukaemia. *Nature* 2018, 562:526–531
 37. Tarlock K, Alonzo TA, Wang Y-C, Gerbing RB, Ries R, Loken MR, Pardo L, Hylkema T, Joaquin J, Sarukkai L, Raimondi SC, Hirsch B, Sung L, Aplenc R, Bernstein I, Gamis AS, Meshinchi S, Pollard JA: Functional properties of KIT mutations are associated with differential clinical outcomes and response to targeted therapeutics in CBF acute myeloid leukemia. *Clin Cancer Res* 2019, 25:5038–5048
 38. Goemans BF, Zwaan CM, Miller M, Zimmermann M, Harlow A, Meshinchi S, Loonen AH, Hähnen K, Reinhardt D, Creutzig U, Kaspers GJL, Heinrich MC: Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. *Leukemia* 2005, 19:1536–1542
 39. Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, Dahl G, Lacayo NJ, Becton D, Chang M, Weinstein HJ, Hirsch B, Raimondi SC, Heerema NA, Woods WG, Lange BJ, Hurwitz C, Arceci RJ, Radich JP, Bernstein ID, Heinrich MC, Meshinchi S: Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. *Blood* 2010, 115:2372–2379
 40. de Rooij JDE, van den Heuvel-Eibrink MM, Hermkens MCH, Verboon LJ, Arentsen-Peters STCJM, Fornerod M, Baruchel A, Stary J, Reinhardt D, de Haas V, Pieters R, Zwaan CM: BCOR and BCORL1 mutations in pediatric acute myeloid leukemia. *Haematologica* 2015, 100:e194–e195
 41. Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, Pigneux A, Wetzler M, Stuart RK, Erba HP, Damon LE, Powel BL, Lindeman N, Steensma DP, Wadleigh M, DeAngelo DJ, Neuberg D, Stone RM, Ebert BL: Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. *Blood* 2015, 125: 1367–1376
 42. Terada K, Yamaguchi H, Ueki T, Usuki K, Kobayashi Y, Tajika K, Gomi S, Kurosawa S, Saito R, Furuta Y, Miyadera K, Tokura T, Marumo A, Omori I, Sakaguchi M, Fujiwara Y, Yui S, Ryotokuji T, Arai K, Kitano T, Wakita S, Fukuda T, Inokuchi K: Usefulness of BCOR gene mutation as a prognostic factor in acute myeloid leukemia with intermediate cytogenetic prognosis. *Genes Chromosomes Cancer* 2018, 57:401–408
 43. Grossmann V, Tiacchi E, Holmes AB, Kohlmann A, Martelli MP, Kern W, et al: Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. *Blood* 2011, 118:6153–6163
 44. Aly M, Ramdzan ZM, Nagata Y, Balasubramanian SK, Hosono N, Makishima H, Visconte V, Kuzmanovic T, Adema V, Nazha A, Przychodzen BP, Kerr CM, Sekeres MA, Abazeed ME, Nepveu A, Maciejewski JP: Distinct clinical and biological implications of CUX1 in myeloid neoplasms. *Blood Adv* 2019, 3:2164–2178
 45. McNeerney ME, Brown CD, Wang XY, Bartom ET, Karmakar S, Bandlamudi C, Yu S, Ko JK, Sandall BP, Stricker T, Anastasi J, Grossman RL, Cunningham JM, Le Beau MM, White KP: CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. *Blood* 2013, 121: 975–983
 46. Wong CC, Martincorena I, Rust AG, Rashid M, Alifrangis C, Alexandrov LB, Tiffen JC, Kober C; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium, Green AR, Massie CE, Nangalia J, Lempidaki S, Döhner H, Döhner K, Bray SJ, McDermott U, Papaemmanuil E, Campbell PJ, Adams DJ: Inactivating CUX1 mutations promote tumorigenesis. *Nat Genet* 2014, 46:33–38
 47. Duployez N, Marceau-Renaut A, Boissel N, Petit A, Bucci M, Geffroy S, Lapillonne H, Renneville A, Ragu C, Figeac M, Celli-Lebras K, Lacombe C, Micol J-B, Abdel-Wahab O, Cornillet P, Ifrah N, Dombret H, Leverger G, Jourdan E, Preudhomme C:

- Comprehensive mutational profiling of core binding factor acute myeloid leukemia. *Blood* 2016, 127:2451–2459
48. Sood R, Hansen NF, Donovan FX, Carrington B, Bucci D, Maskeri B, Young A, Trivedi NS, Kohlschmidt J, Stone RM, Caligiuri MA, Chandrasekharappa SC, Marcucci G, Mullikin JC, Bloomfield CD, Liu P: Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia. *Leukemia* 2016, 30:501–504
 49. de Rooij JDE, van den Heuvel-Eibrink MM, van de Rijdt NKAM, Verboon LJ, de Haas V, Trka J, Baruchel A, Reinhardt D, Pieters R, Fornerod M, Zwaan CM: PHF6 mutations in paediatric acute myeloid leukaemia. *Br J Haematol* 2016, 175:967–971
 50. Stratmann S, Yones SA, Mayrhofer M, Norgren N, Skaftason A, Sun JT, Smolinska K, Komorowski J, Herlin MK, Sundström C, Eriksson A, Höglund M, Palle J, Abrahamsson J, Jahnukainen K, Munthe-Kaas MC, Zeller B, Tamm KP, Cavelier L, Holmfeldt L: Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets. *Blood Adv* 2021, 5:900–912
 51. Reinhardt D, Antoniou E, Waack K: Pediatric acute myeloid leukemia—past, present, and future. *J Clin Med* 2022, 11:504
 52. Eisfeld A-K, Kohlschmidt J, Mims A, Nicolet D, Walker CJ, Blachly JS, Carroll AJ, Papaioannou D, Kolitz JE, Powell BE, Stone RM, de la Chapelle A, Byrd JC, Mrózek K, Bloomfield CD: Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years. *Leukemia* 2020, 34:3215–3227
 53. Gardin C, Pautas C, Fournier E, Itzykson R, Lemasle E, Bourhis J-H, Adès L, Marolleau J-P, Malfuson JV, Gastaud L, Raffoux E, Lambert J, Braun T, Thomas X, Chantepie S, Cluzeau T, de Botton S, Berthon C, Boissel N, Duployez N, Terré C, Peffault de Latour R, Michallet M, Celli-Lebras K, Preudhomme C, Dombret H: Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. *Blood Adv* 2020, 4:1942–1949
 54. Herold T, Rothenberg-Thurley M, Grunwald VV, Janke H, Goerlich D, Sauerland MC, Konstandin NP, Dufour A, Schneider S, Neusser M, Ksienzyk B, Greif PA, Subklewe M, Faldum A, Bohlander SK, Braess J, Wörmann B, Krug U, Berdel WE, Hiddemann W, Spiekermann K, Metzeler KH: Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. *Leukemia* 2020, 34:3161–3172
 55. Tazi Y, Arango-Ossa JA, Zhou Y, Bernard E, Thomas I, Gilkes A, Freeman S, Pradat Y, Johnson SJ, Hills R, Dillon R, Levine MF, Leongamornlert D, Butler A, Ganser A, Bullinger L, Döhner K, Ottmann O, Adams R, Döhner H, Campbell P, Burnett AK, Dennis M, Russell NH, Devlin SM, Huntly BJP, Papaemmanuil E: Unified classification and risk-stratification in acute myeloid leukemia. *Nat Commun* 2022, 13:4622
 56. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele GJ, Röllig C, Sierra J, Stein EM, Tallman MS, Tien H-F, Wang J, Wierzbowska A, Löwenberg B: Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. *Blood* 2022, 140:1345–1377
 57. Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B, Franklin JL, Radich JP, Meshinchi S: Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. *Blood* 2009, 113:6558–6566
 58. Hollink IHIM, van den Heuvel-Eibrink MM, Arentsen-Peters STCJM, Zimmermann M, Peeters JK, Valk PJM, Balgobind BV, Sonneveld E, Kaspers GJL, de Bont ESJM, Trka J, Baruchel A, Creutzig U, Pieters R, Reinhardt D, Zwaan CM: Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia. *Haematologica* 2011, 96:384–392
 59. Matsuo H, Kajihara M, Tomizawa D, Watanabe T, Saito AM, Fujimoto J, Horibe K, Kodama K, Tokumasu M, Itoh H, Nakayama H, Kinoshita A, Taga T, Tawa A, Taki T, Tanaka S, Adachi S: Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group. *Blood Cancer J* 2014, 4:e226
 60. Umeda M, Ma J, Huang BJ, Hagiwara K, Westover T, Abdelhamed S, et al: Integrated genomic analysis identifies UBTF tandem duplications as a recurrent lesion in pediatric acute myeloid leukemia. *Blood Cancer Discov* 2022, 3:194–207